23. EFFICACY, SAFETY AND ECONOMIC EVALUATION OF SUBCUTANEOUS RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PATIENTS WITH NON-HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW. YHCĐ 2024, 65 (CĐ 12 - Bệnh viện Thủ Đức). https://doi.org/10.52163/yhc.v65iCD12.1833.